GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Deferred Tax

Enlivex Therapeutics (FRA:1BT) Deferred Tax : €0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Enlivex Therapeutics Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Enlivex Therapeutics's change in deferred tax for the three months ended in Dec. 2023 was €0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Enlivex Therapeutics Deferred Tax Historical Data

The historical data trend for Enlivex Therapeutics's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Deferred Tax Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enlivex Therapeutics Deferred Tax Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (FRA:1BT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Deferred Tax
Comparable Companies
RGLS CRBP VIRX CRIS ORGS CLRB AGE MRKR CLCS AURX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ENLV:USA ENLV:Israel
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Website
https://www.enlivex.com
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (FRA:1BT) Headlines

No Headlines